JP2014070075A5 - - Google Patents

Download PDF

Info

Publication number
JP2014070075A5
JP2014070075A5 JP2013228826A JP2013228826A JP2014070075A5 JP 2014070075 A5 JP2014070075 A5 JP 2014070075A5 JP 2013228826 A JP2013228826 A JP 2013228826A JP 2013228826 A JP2013228826 A JP 2013228826A JP 2014070075 A5 JP2014070075 A5 JP 2014070075A5
Authority
JP
Japan
Prior art keywords
dihydrobenzo
triazol
oxazepin
imidazo
isopropyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013228826A
Other languages
English (en)
Japanese (ja)
Other versions
JP5625101B2 (ja
JP2014070075A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2014070075A publication Critical patent/JP2014070075A/ja
Publication of JP2014070075A5 publication Critical patent/JP2014070075A5/ja
Application granted granted Critical
Publication of JP5625101B2 publication Critical patent/JP5625101B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013228826A 2009-09-28 2013-11-01 ベンゾオキサゼピンpi3k阻害剤化合物及び使用方法 Active JP5625101B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US24638109P 2009-09-28 2009-09-28
US61/246,381 2009-09-28
US33068510P 2010-05-03 2010-05-03
US61/330,685 2010-05-03

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2012530282A Division JP5540101B2 (ja) 2009-09-28 2010-09-27 ベンゾオキサゼピンpi3k阻害剤化合物及び使用方法

Publications (3)

Publication Number Publication Date
JP2014070075A JP2014070075A (ja) 2014-04-21
JP2014070075A5 true JP2014070075A5 (cg-RX-API-DMAC7.html) 2014-08-07
JP5625101B2 JP5625101B2 (ja) 2014-11-12

Family

ID=43037239

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012530282A Active JP5540101B2 (ja) 2009-09-28 2010-09-27 ベンゾオキサゼピンpi3k阻害剤化合物及び使用方法
JP2013228826A Active JP5625101B2 (ja) 2009-09-28 2013-11-01 ベンゾオキサゼピンpi3k阻害剤化合物及び使用方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2012530282A Active JP5540101B2 (ja) 2009-09-28 2010-09-27 ベンゾオキサゼピンpi3k阻害剤化合物及び使用方法

Country Status (31)

Country Link
US (7) US8242104B2 (cg-RX-API-DMAC7.html)
EP (3) EP2845592A1 (cg-RX-API-DMAC7.html)
JP (2) JP5540101B2 (cg-RX-API-DMAC7.html)
KR (1) KR101428346B1 (cg-RX-API-DMAC7.html)
CN (2) CN104744491B (cg-RX-API-DMAC7.html)
AR (1) AR078187A1 (cg-RX-API-DMAC7.html)
AU (1) AU2010299816C1 (cg-RX-API-DMAC7.html)
BR (1) BR112012006807A2 (cg-RX-API-DMAC7.html)
CA (1) CA2772691C (cg-RX-API-DMAC7.html)
CL (1) CL2012000754A1 (cg-RX-API-DMAC7.html)
CO (1) CO6491026A2 (cg-RX-API-DMAC7.html)
CR (1) CR20120121A (cg-RX-API-DMAC7.html)
DK (1) DK2483278T3 (cg-RX-API-DMAC7.html)
EC (1) ECSP12011755A (cg-RX-API-DMAC7.html)
ES (2) ES2444779T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20140229T1 (cg-RX-API-DMAC7.html)
IL (2) IL217558A (cg-RX-API-DMAC7.html)
MA (1) MA33531B1 (cg-RX-API-DMAC7.html)
MX (1) MX2012003591A (cg-RX-API-DMAC7.html)
MY (2) MY184074A (cg-RX-API-DMAC7.html)
NZ (1) NZ597833A (cg-RX-API-DMAC7.html)
PE (1) PE20121025A1 (cg-RX-API-DMAC7.html)
PL (1) PL2483278T3 (cg-RX-API-DMAC7.html)
PT (1) PT2483278E (cg-RX-API-DMAC7.html)
RS (1) RS53164B (cg-RX-API-DMAC7.html)
RU (2) RU2600927C2 (cg-RX-API-DMAC7.html)
SG (1) SG10201405049RA (cg-RX-API-DMAC7.html)
SI (1) SI2483278T1 (cg-RX-API-DMAC7.html)
TW (1) TWI423980B (cg-RX-API-DMAC7.html)
WO (1) WO2011036280A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201202199B (cg-RX-API-DMAC7.html)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA025824B1 (ru) 2009-07-27 2017-02-28 Джилид Сайэнс, Инк. Конденсированные гетероциклические соединения в качестве модуляторов ионных каналов
BR112012006807A2 (pt) * 2009-09-28 2020-11-03 F.Hoffmann-La Roche Ag compostos da fórmula i, composição farmacêutica, composta por composto, método de tratamento de câncer em um mamífero, uso de um composto, kit para tratar um condição mediada por pi3k e processo para a preparação de um composto
BR112012006802A2 (pt) 2009-09-28 2020-08-18 F.Hoffmann-La Roche Ag composto, composição farmacêutica, método para tratar câncer, usos de um composto, kit e invenção
BR112012033402A2 (pt) 2010-07-02 2017-01-24 Gilead Sciences Inc moduladores de canais de íons conforme os compostos heterocíclicos fundidos
RU2013143747A (ru) * 2011-03-21 2015-04-27 Ф. Хоффманн-Ля Рош Аг Соединения бензоксазепина, селективные в отношении pi3k p110 дельта и способы их применения
WO2012154760A1 (en) 2011-05-10 2012-11-15 Gilead Sciences, Inc. Fused heterocyclic compounds as sodium channel modulators
WO2012156379A1 (en) 2011-05-13 2012-11-22 Universität Zürich PIK3/P110α INHIBITORS FOR PREVENTION OF RESTENOSIS BY APPLICATION AS AN IMPLANT COATING
TWI549944B (zh) 2011-07-01 2016-09-21 吉李德科學股份有限公司 作為離子通道調節劑之稠合雜環化合物
NO3175985T3 (cg-RX-API-DMAC7.html) 2011-07-01 2018-04-28
RU2014136578A (ru) 2012-02-17 2016-04-10 Ф. Хоффманн-Ля Рош Аг Трициклические соединения и способы их применения
HK1202265A1 (en) * 2012-06-08 2015-09-25 霍夫曼-拉罗奇有限公司 Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer
MX367055B (es) 2012-06-26 2019-08-02 Del Mar Pharmaceuticals El uso de una composición que comprende dianhidrogalactitol, diacetildianhidrogalactitol, y dibromodulcitol, y análogos o derivados de cada uno para el tratamiento de malignidades resistentes a inhibidores de tirosina cinasa.
CN102775395A (zh) * 2012-07-12 2012-11-14 江苏七洲绿色化工股份有限公司 一种丙环唑的制备方法及丙环唑中间体
US9303046B2 (en) * 2012-08-07 2016-04-05 Janssen Pharmaceutica Nv Process for the preparation of heterocyclic ester derivatives
CN108929333A (zh) * 2013-03-13 2018-12-04 豪夫迈·罗氏有限公司 制备苯并氧氮杂*化合物的方法
CN105492011A (zh) 2013-04-08 2016-04-13 丹尼斯·M·布朗 不理想给药化学化合物的治疗增效
TWI638818B (zh) * 2013-12-16 2018-10-21 赫孚孟拉羅股份公司 2-(4-(2-(1-異丙基-3-甲基-1h-1,2,4-三唑-5-基)-5,6-二氫苯并[f]咪唑并[1,2-d][1,4]氧氮呯-9-基)-1h-吡唑-1-基)-2-甲基丙醯胺之多晶型、製造方法及醫藥用途
WO2015136016A2 (en) 2014-03-13 2015-09-17 F. Hoffmann-La Roche Ag Therapeutic combinations with estrogen receptor modulators
US10183934B2 (en) 2015-02-02 2019-01-22 Forma Therapeutics, Inc. Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors
SG11201706146UA (en) 2015-02-02 2017-08-30 Forma Therapeutics Inc 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as hdac inhibitors
AR104068A1 (es) 2015-03-26 2017-06-21 Hoffmann La Roche Combinaciones de un compuesto inhibidor de fosfoinosítido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cáncer
US10351576B2 (en) * 2015-04-30 2019-07-16 Novartis Ag Fused tricyclic pyrazole derivatives useful for farnesoid X receptors
JP6871919B2 (ja) 2015-06-16 2021-05-19 ナノファギックス エルエルシー 薬物送達及びイメージング化学コンジュゲート、製剤及びその使用方法
KR20180012324A (ko) 2015-06-29 2018-02-05 에프. 호프만-라 로슈 아게 타셀리십을 사용하는 치료 방법
TWI601732B (zh) * 2015-07-02 2017-10-11 赫孚孟拉羅股份公司 苯并氧氮呯噁唑啶酮化合物及其用途
WO2017001658A1 (en) 2015-07-02 2017-01-05 F. Hoffmann-La Roche Ag Benzoxazepin oxazolidinone compounds and methods of use
CN112409378A (zh) * 2015-09-08 2021-02-26 豪夫迈·罗氏有限公司 三环pi3k抑制剂化合物及其使用方法
US9721369B2 (en) * 2015-09-15 2017-08-01 Facebook, Inc. Systems and methods for utilizing multiple map portions from multiple map data sources
WO2017218950A1 (en) 2016-06-17 2017-12-21 Forma Therapeutics, Inc. 2-spiro-5- and 6-hydroxamic acid indanes as hdac inhibitors
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
WO2018060091A1 (en) 2016-09-29 2018-04-05 Bayer Cropscience Aktiengesellschaft Novel 5-substituted imidazolylmethyl derivatives
AU2017378188B2 (en) * 2016-12-15 2020-11-26 F. Hoffmann-La Roche Ag Process for the preparation of (S)-2-((2-((S)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino) propanamide
JP6992081B2 (ja) 2017-03-02 2022-02-03 ジェネンテック, インコーポレイテッド Her2陽性乳癌のアジュバント治療
EP4534148A3 (en) 2017-04-28 2025-05-21 F. Hoffmann-La Roche AG Polymorphs and solid forms of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide, and methods of production
WO2019084459A1 (en) * 2017-10-26 2019-05-02 Xynomic Pharmaceuticals, Inc. CRYSTALLINE SALTS AND FORMS OF B-RAF KINASE INHIBITOR
AU2019276514B2 (en) * 2018-05-30 2023-12-14 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Inhibitor containing tricyclic derivative, preparation method therefor, and application thereof
CN111909157B (zh) * 2019-05-07 2023-02-03 南京药石科技股份有限公司 Ezh2抑制剂及其用途
CN114599656A (zh) * 2019-11-04 2022-06-07 贝达药业股份有限公司 咪唑烷酮类化合物及其制备方法与应用
EP4056575A4 (en) * 2019-11-04 2023-11-08 Betta Pharmaceuticals Co., Ltd IMIDAZOLIDINONE COMPOUND, PROCESS THEREOF AND USE THEREOF
CA3159094A1 (en) * 2019-11-25 2021-06-03 Shanghai Hansoh Biomedical Co., Ltd. Three fused ring derivative-containing salt or crystal form and pharmaceutical composition thereof
KR20240004634A (ko) * 2021-05-03 2024-01-11 산동 수안주 파마 코포레이션 리미티드 삼환식 유비퀴틴 특이적 프로테아제 1 억제제 및 이의 용도
AU2022275275A1 (en) * 2021-05-13 2023-12-14 Betta Pharmaceuticals Co., Ltd Polymorph of imidazolidinone compound, preparation method therefor and use thereof
TW202313563A (zh) 2021-05-28 2023-04-01 美商建南德克公司 苯并氧氮呯噁唑啶酮化合物之製備方法
WO2024104435A1 (zh) * 2022-11-17 2024-05-23 微境生物医药科技(上海)有限公司 三并环类PI3Kα抑制剂及其制备方法和医药用途
CN116003280B (zh) * 2022-12-30 2024-11-19 合肥工业大学 一种芳基甲酰胺类化合物的光化学合成方法
WO2025082533A1 (zh) * 2023-10-21 2025-04-24 上海轶诺药业有限公司 一种稠环化合物及其制备和应用
WO2025237374A1 (zh) * 2024-05-16 2025-11-20 微境生物医药科技(上海)有限公司 PI3Kα抑制剂及其制备方法和医药用途

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
GB8504702D0 (en) * 1985-02-23 1985-03-27 Zyma Sa Tricyclic compounds
US5583024A (en) 1985-12-02 1996-12-10 The Regents Of The University Of California Recombinant expression of Coleoptera luciferase
FR2677356B1 (fr) * 1991-06-05 1995-03-17 Sanofi Sa Derives heterocycliques d'acylamino-2 thiazoles-5 substitues, leur preparation et compositions pharmaceutiques en contenant.
FI943948L (fi) * 1992-12-28 1994-08-26 Eisai Co Ltd Heterosykliset hiilihappojohdannaiset
AU678503B2 (en) * 1993-09-24 1997-05-29 Takeda Chemical Industries Ltd. Condensed heterocyclic compounds and their use as squalene synthetase inhibitors
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
JPH08336393A (ja) 1995-04-13 1996-12-24 Mitsubishi Chem Corp 光学活性なγ−置換−β−ヒドロキシ酪酸エステルの製造法
WO1997019087A1 (en) * 1995-11-17 1997-05-29 E.I. Du Pont De Nemours And Company Tricyclic herbicidal heterocycles
US6602677B1 (en) 1997-09-19 2003-08-05 Promega Corporation Thermostable luciferases and methods of production
DE19908537A1 (de) * 1999-02-26 2000-08-31 Aventis Pharma Gmbh Verwendung von polycyclischen 2-Amino-Thiazol Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
DE19908535A1 (de) * 1999-02-26 2000-08-31 Aventis Pharma Gmbh Verwendung von polycyclischen Thiazol-Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
DE19908538A1 (de) * 1999-02-26 2000-08-31 Aventis Pharma Gmbh Polycyclische 2-Amino-Thiazol Systeme, Verfahren zu ihrer Herstellung und Arzneimittel enthaltend diese Verbindungen
DE19908533A1 (de) * 1999-02-26 2000-08-31 Aventis Pharma Gmbh Polycyclische Thiazol-Systeme, Verfahren zu ihrer Herstellung und Arzneimittel enthaltend diese Verbindungen
US7273880B2 (en) * 1999-06-30 2007-09-25 H. Lunbeck A/S Selective NPY (Y5) antagonists
WO2001064675A1 (en) 2000-03-03 2001-09-07 Novartis Ag Condensed thiazolamines and their use as neuropeptide y5 antagonists
CN1575273A (zh) 2001-02-02 2005-02-02 先灵公司 作为cxc趋化因子受体拮抗剂的3.4-二-取代环丁烯-1,2-二酮类化合物
TWI232863B (en) * 2001-06-11 2005-05-21 Akzo Nobel Nv Benzoxazepine derivatives
AU2003256650A1 (en) * 2002-07-19 2004-02-09 Pharmacia Corporation Substituted thiophene carboxamide compounds for the treatment of inflammation
MXPA05008400A (es) * 2003-02-07 2005-10-05 Warner Lambert Co Derivados de oxazolidinona n-sustituidos por un anillo triciclico, para su uso como agentes antibacterianos.
TW200510356A (en) * 2003-08-01 2005-03-16 Takeda Chemical Industries Ltd Benzoxaepine compounds
US20050239767A1 (en) * 2003-10-28 2005-10-27 Chan Michael K Intermolecular SNAr of the heterocycle-activated nitro and fluoro groups-application in the synthesis of polyazamacrocyclic ligands
KR20070039885A (ko) * 2004-07-01 2007-04-13 머크 앤드 캄파니 인코포레이티드 유사분열 키네신 억제제
WO2006040279A1 (de) * 2004-10-07 2006-04-20 Boehringer Ingelheim International Gmbh Pi3-kinasen
CA2622755C (en) 2005-10-07 2017-01-31 Exelixis, Inc. Azetidines as mek inhibitors
US20070238718A1 (en) * 2006-04-06 2007-10-11 Matthias Grauert Thiazolyl-dihydro-indazole
US20070238746A1 (en) * 2006-04-06 2007-10-11 Trixi Brandl Thiazolyl-dihydro-chinazoline
GB0610866D0 (en) * 2006-06-02 2006-07-12 Hammersmith Imanet Ltd Novel in vivo imaging compounds
CA2659280A1 (en) * 2006-07-28 2008-01-31 Alcan Packaging Flexible France Coextruded film with polylactic acid (pla) and ethylene vinyl acetate (eva)
AU2007281911B2 (en) 2006-08-04 2014-02-06 Beth Israel Deaconess Medical Center Inhibitors of pyruvate kinase and methods of treating disease
US8779154B2 (en) * 2006-09-26 2014-07-15 Qinglin Che Fused ring compounds for inflammation and immune-related uses
AU2007341232B2 (en) * 2006-12-29 2013-01-31 AbbVie Deutschland GmbH & Co. KG Carboxamide compounds and their use as calpain inhibitors
US8101740B2 (en) 2007-09-19 2012-01-24 The Regents Of The University Of California Positron emission tomography probes for imaging immune activation and selected cancers
CN102333779B (zh) 2008-03-31 2015-12-09 吉宁特有限公司 苯并吡喃和苯并氧杂*pi3k抑制剂化合物和使用方法
US8653097B2 (en) * 2008-10-17 2014-02-18 Boehringer Ingelheim International Gmbh Tetra-aza-heterocycles as phosphatidylinositol-3-kinases (P13-kinases) inhibitor
BR112012006802A2 (pt) * 2009-09-28 2020-08-18 F.Hoffmann-La Roche Ag composto, composição farmacêutica, método para tratar câncer, usos de um composto, kit e invenção
BR112012006807A2 (pt) * 2009-09-28 2020-11-03 F.Hoffmann-La Roche Ag compostos da fórmula i, composição farmacêutica, composta por composto, método de tratamento de câncer em um mamífero, uso de um composto, kit para tratar um condição mediada por pi3k e processo para a preparação de um composto

Similar Documents

Publication Publication Date Title
JP2014070075A5 (cg-RX-API-DMAC7.html)
NZ597833A (en) Benzoxazepin pi3k inhibitor compounds and methods of use
HRP20210981T1 (hr) Imidazolonil kinolini i njihova uporaba kao inhibitori atm kinaze
JP2013529611A5 (cg-RX-API-DMAC7.html)
HRP20161674T1 (hr) 4-(8-METOKSI-1-((1-METOKSIPROPAN-2-IL)-2-(TETRAHIDRO-2H-PIRAN-4-IL)-1H-IMIDAZO[4,5-c]KINOLIN-7-IL)-3,5-DIMETILIZOKSAZOL I NJEGOVA UPOTREBA KAO INHIBITORA BROMODOMENE
MX2022015026A (es) Compuesto heteroaromatico de imidazol de cinco miembros y uso del mismo.
JP2016501221A5 (cg-RX-API-DMAC7.html)
MX2010001745A (es) Imidazoles fusionados para el tratamiento del cancer.
ME01462B (me) Vinilindazolilna jedinjenja"
AR102487A1 (es) Derivados de feniltriazol sustituido con hidroxialquilo y sus usos
HRP20150489T1 (hr) Imidazo[4,5-c]kinolini kao inhibitori dna-pk
JO3392B1 (ar) مركبات عطرية حلقية غير متجانسة كمركبات مضادة للالتهاب
WO2016160617A3 (en) Inhibitors of cyclin-dependent kinases
JP2011517457A5 (cg-RX-API-DMAC7.html)
MX383051B (es) Compuestos que inhiben eif4a y métodos relacionados a los mismos.
JP2013510124A5 (cg-RX-API-DMAC7.html)
JP2017524668A5 (cg-RX-API-DMAC7.html)
IL274936B2 (en) Transmuted heterocyclic bicyclic compounds as prmt5 inhibitors
NZ601077A (en) Use of an adrenal hormone-modifying agent
NZ586579A (en) Fused heterocyclic derivatives and methods of use as c-met inhibitors
JP2014533745A5 (cg-RX-API-DMAC7.html)
RU2021102805A (ru) 4,6-ЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-a]ПИРАЗИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-КИНАЗЫ
JP2013502441A5 (cg-RX-API-DMAC7.html)
JP2017512803A5 (cg-RX-API-DMAC7.html)
CL2016003175A1 (es) Compuestos de [1, 2, 4 ] triazol e imidazol sustituidos